Simplex Trading LLC Acquires Shares of 1,292 Inogen Inc (INGN)

Simplex Trading LLC acquired a new stake in Inogen Inc (NASDAQ:INGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,292 shares of the medical technology company’s stock, valued at approximately $153,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Schroder Investment Management Group purchased a new stake in shares of Inogen during the second quarter worth about $132,000. Ameritas Investment Partners Inc. increased its stake in shares of Inogen by 6.1% during the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 86 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Inogen by 17.8% during the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after purchasing an additional 307 shares in the last quarter. Pinebridge Investments L.P. boosted its position in Inogen by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock worth $204,000 after acquiring an additional 33 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Inogen during the third quarter worth about $213,000.

In related news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $94.07, for a total transaction of $1,316,980.00. Following the sale, the director now directly owns 7,808 shares of the company’s stock, valued at approximately $734,498.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $112.35, for a total transaction of $280,875.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,500 shares of company stock worth $9,267,695. Company insiders own 5.31% of the company’s stock.

A number of research firms recently weighed in on INGN. Zacks Investment Research lowered shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday. BidaskClub lowered shares of Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Needham & Company LLC boosted their price target on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. Finally, Leerink Swann restated an “outperform” rating and set a $120.00 price target (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $102.71.

Inogen Inc (NASDAQ INGN) opened at $114.22 on Thursday. The firm has a market cap of $2,430.00, a PE ratio of 79.87, a price-to-earnings-growth ratio of 4.06 and a beta of 1.13. Inogen Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05.

Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The company had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. During the same period in the previous year, the business posted $0.25 EPS. Inogen’s revenue was up 26.8% on a year-over-year basis. research analysts expect that Inogen Inc will post 1.19 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/01/11/simplex-trading-llc-acquires-shares-of-1292-inogen-inc-ingn.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply